Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Janssen Sciences Ireland Unlimited CofiledCriticalViiv Healthcare Co
Publication of BR112022006267A2publicationCriticalpatent/BR112022006267A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
MÉTODO PARA TRATAR HIV COM CABOTEGRAVIR E RILPIVIRINA. Inventados são métodos para o tratamento de HIV em um ser humano em necessidade do mesmo, que compreende a administração de uma quantidade terapeuticamente eficaz de uma combinação de cabotegravir ou um sal farmaceuticamente aceitável do mesmo e rilpivirina ou um sal farmaceuticamente aceitável do mesmo, a tal ser humano.METHOD TO TREAT HIV WITH CABOTEGRAVIR AND RILPIVIRINE. Invented are methods for treating HIV in a human in need thereof, which comprise administering a therapeutically effective amount of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, to such human being.
BR112022006267A2019-10-012020-10-01
METHOD TO TREAT HIV WITH CABOTEGRAVIR AND RILPIVIRINE
BR112022006267A2
(en)
composition, method, risk reduction method, prevention or treatment of an individual having an autoimmune disease or disorder, method of inducing degradation of a target protein in a cell, method for reducing risk, preventing or treating a disease state or disorder in a patient wherein the unregulated protein activity is responsible for said disease or condition, method for reducing the risk, preventing or treating cancer in an individual, and method of treating a genetic disease or disorder in an individual